Histogram Analysis of MR Imaging–Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes

References

1. ↵
   Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309–31

   PubMedWeb of Science
2. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 2006;238:658–67

   CrossRefPubMedWeb of Science
3. ↵
   Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528–37

   Abstract/FREE Full Text
4. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990;176:211–20

   PubMed
5. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

   PubMedWeb of Science
6. ↵
   Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98

   CrossRefPubMedWeb of Science
7. ↵
   Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214–21

   Abstract/FREE Full Text
8. ↵
   Papadimitrou JM, Woods AE. Structural and functional characteristics of the microcirculation in neoplasms. J Pathol 1975;116:65–72

   CrossRefPubMed
9. ↵
   Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer;2007
10. ↵
    Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73

    Abstract/FREE Full Text
11. ↵
    Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist 2006;11:681–93

    Abstract/FREE Full Text
12. ↵
    Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002;103:267–75. Epub 2001 Nov 22

    CrossRefPubMedWeb of Science
13. ↵
    Godfraind C, Rousseau E, Ruchoux MM, et al. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 2003;29:462–71

    CrossRefPubMed
14. ↵
    Kim SH, Kim H, Kim TS. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol 2005;110:27–38. Epub 2005 May 26.

    CrossRefPubMedWeb of Science
15. ↵
    Jenkinson MD, Smith TS, Joyce KA. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703–13

    CrossRefPubMedWeb of Science
16. ↵
    Law M, Brodsky JE, Babb J, et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007;25:1113–19

    CrossRefPubMed
17. ↵
    Barbashina V, Salazar P, Holland EC, et al. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11:1119–28

    Abstract/FREE Full Text
18. ↵
    Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479–89

    PubMedWeb of Science
19. ↵
    Emblem K, Nedregaard B, Nome T, et al. Glioma grading using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 2008;247 ;808–17

    CrossRefPubMedWeb of Science
20. ↵
    Law M, Young R, Babb J, et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 2007;28:761–66

    Abstract/FREE Full Text
21. ↵
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–79

    Abstract/FREE Full Text
22. ↵
    Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45

    Abstract/FREE Full Text
23. ↵
    Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91

    Abstract/FREE Full Text
24. ↵
    Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–65

    PubMedWeb of Science
25. ↵
    Ostergaard L, Weisskoff RM, Chesler DA, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I. Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715–25

    CrossRefPubMedWeb of Science
26. ↵
    Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67

    Abstract/FREE Full Text
27. ↵
    Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
28. ↵
    Maes F, Collignon A, Vandermeulen D, et al. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187–98

    CrossRefPubMedWeb of Science
29. ↵
    Scheie D, Andresen PA, Cvancarova M, et al. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 2006;30:828–37

    CrossRefPubMedWeb of Science
30. ↵
    Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004;25:1524–32

    Abstract/FREE Full Text
31. ↵
    Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88–94

    Abstract/FREE Full Text